Drug Trial Radar · NCT00578929
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
Last checked: Nov 19, 2026Latest source record: Mar 2, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,388
Actual
Start
Sep 2007
Primary completion
Nov 2008
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Dec 21, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.
Conditions
- Seasonal Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%Drug
Olopatadine HCl 1 or 2 sprays per nostril twice daily
VehicleDrug
Vehicle 1 or 2 sprays per nostril twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)Time frame: Baseline through 2 weeks after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kenilworth/IL
Kenilworth, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.